Co-Diagnostics
CODX

$1.27

0.79%

Market Cap: $40.5M

About: Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.

Employees: 155

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

33% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 9

18% more capital invested

Capital invested by funds: $4.91M [Q1] → $5.81M (+$896K) [Q2]

13% more funds holding

Funds holding: 39 [Q1] → 44 (+5) [Q2]

0.84% more ownership

Funds ownership: 14.0% [Q1] → 14.84% (+0.84%) [Q2]

69% less call options, than puts

Call options by funds: $79K | Put options by funds: $252K

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$1.50

18%

upside

Avg. target

$1.75

38%

upside

High target

$2

57%

upside

2 analyst ratings

0 positive

0%

2 neutral

100%

0 negative

0%

HC Wainwright & Co. Yi Chen 33% 1-year accuracy 44 / 132 met price target	18%upside $1.50	Neutral Maintained	12 Aug 2024
HC Wainwright & Co. Yi Chen 33% 1-year accuracy 44 / 132 met price target	57%upside $2	Neutral Reiterated	17 Jun 2024

See Analyst Rankings

Financial journalist opinion

Co-Diagnostics, Inc. Completes Updated Clade Ib Analysis of 2-Gene Mpox RUO Test

SALT LAKE CITY , Sept. 5, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has performed an in silico analysis of the Co-Dx™ Logix Smart® Mpox (2-Gene) RUO test to evaluate the possible impact of clade Ib mpox on the test.

Co-Diagnostics, Inc. Completes Updated Clade Ib Analysis of 2-Gene Mpox RUO Test

Co-Diagnostics, Inc. to Present at 16th Next Generation Dx Summit in Washington, D.C.

SALT LAKE CITY , Aug. 15, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be sponsoring, presenting and hosting a booth at the 16th Annual Next Generation Dx Summit, held virtually and in-person in Washington, D.C. on August 19-21, 2024.

Co-Diagnostics, Inc. to Present at 16th Next Generation Dx Summit in Washington, D.C.

Co-Diagnostics, Inc. (CODX) Q2 2024 Earnings Call Transcript

Co-Diagnostics, Inc. (NASDAQ:CODX ) Q2 2024 Results Conference Call August 8, 2024 4:30 PM ET Company Participants Andrew Benson - Head, Investor Relations Dwight Egan - Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Jade Montgomery - H.C. Wainwright Operator Good day, and welcome to the Co-Diagnostics Second Quarter 2024 Earnings Conference Call.

Co-Diagnostics, Inc. (CODX) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Tops Revenue Estimates

Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.31 per share a year ago.

Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Tops Revenue Estimates

Co-Diagnostics, Inc. Reports Second Quarter 2024 Financial Results

SALT LAKE CITY , August 8, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended June 30, 2024. Second Quarter 2024 Financial Results: Revenue of $2.7 million, up from $0.2 million during the prior year primarily due to the achievement of certain milestones under various grant agreements the company was awarded Operating expenses of $10.1 million decreased by 13.7% from the prior year due to lower stock-based compensation expense, bad debt expense, and expenses related to clinical trials for the Co-Dx PCR platform Operating loss of $7.7 million compared to operating loss of $12.0 million in 2023 Net loss of $7.6 million, compared to net loss of $8.9 million in the prior year, representing a loss of $0.25 per fully diluted share, compared to a loss of $0.31 per fully diluted share in the prior year Adjusted EBITDA loss of $5.9 million compared to $9.6 million in the prior year Cash, cash equivalents, and marketable securities of $44.9 million as of June 30, 2024 Second Quarter and Recent 2024 Business Highlights: Submitted first 510(k) application to the U.S. Food and Drug Administration (FDA) for the Co-Dx™ PCR Pro™ Platform, which includes the Co-Dx PCR Pro instrument and the Co-Dx PCR COVID-19 test for over-the-counter (OTC) use Inaugurated a new manufacturing facility in South Salt Lake to manufacture our patented Co-Primers® oligonucleotides, the Co-Dx™ PCR Pro™ instrument, and test cups for the new Co-Dx PCR platform Expanded Co-Dx vector control technology to a 15th U.S. state, Nevada, which includes Vector Smart® PCR tests in environmental surveillance of mosquito pools for mosquito-borne illnesses Attended and participated in the FIME 2024 trade show in Miami Beach, Florida, which included exhibitors from 116 countries and over 15,000 professional attendees, to display the new Co-Dx PCR platform "We are very pleased by the progress Co-Diagnostics has made so far this year," said Dwight Egan, Co-Diagnostics' Chief Executive Officer.

Co-Diagnostics, Inc. Reports Second Quarter 2024 Financial Results

Co-Diagnostics, Inc. to Host Booth and Discuss Advancing POC/OTC Diagnostics at ADLM 2024 in Chicago

SALT LAKE CITY , July 29, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is hosting a booth at the Association for Diagnostics & Laboratory Medicine (ADLM) annual meeting and expo held July 28-August 1, 2024, in Chicago, IL. Co-Dx will also be holding a special company presentation to discuss the role of its new at-home and point-of-care Co-Dx™ PCR platform* in closing the global diagnostics gap for an array of potential indications, including tuberculosis (TB).

Co-Diagnostics, Inc. to Host Booth and Discuss Advancing POC/OTC Diagnostics at ADLM 2024 in Chicago

Co-Diagnostics, Inc. Announces Second Quarter 2024 Earnings Release Date and Webcast

SALT LAKE CITY , July 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2024 results on Thursday, August 8, 2024, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.

Co-Diagnostics, Inc. Announces Second Quarter 2024 Earnings Release Date and Webcast

Co-Diagnostics, Inc. Expands Vector Control Customer Base to 25 Customers across 15 U.S. States

SALT LAKE CITY , July 2, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx™"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that use of the Company's vector control technology will expand to the 15th U.S. state following an installation in Nevada next week. Co-Dx vector control technology includes Vector Smart® PCR tests used in environmental (non-diagnostic) surveillance of mosquito pools for mosquito-borne illnesses like West Nile virus, Zika, dengue and chikungunya.

Co-Diagnostics, Inc. Expands Vector Control Customer Base to 25 Customers across 15 U.S. States

Co-Diagnostics, Inc. to Participate at FIME 2024 in Miami Beach, June 19-21

SALT LAKE CITY , June 18, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has been invited to participate in the Utah booth at the FIME trade show in Miami Beach, Florida, on June 19-21. FIME is described as the Americas' leading medical trade expo for medical device and product purchasers, for establishing new supplier relationships, and for strengthening business ties with the global medical device and equipment market, with exhibitors from 116 countries and more than 15,000 expected professional attendees.

Co-Diagnostics, Inc. to Participate at FIME 2024 in Miami Beach, June 19-21

Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

The Company expects that the application for OTC clearance will shortly be followed by pursuit of POC clearance, with other tests in the pipeline to meet the needs of a global market SALT LAKE CITY , June 14, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has completed its first U.S. Food and Drug Administration (FDA) application for 510(k) clearance for the Co-Dx™ PCR Pro™ instrument, and the Co-Dx PCR COVID-19 Test for over-the-counter (OTC) use. Co-Diagnostics completed the submission via the FDA's electronic Submissions Template And Resource (eSTAR) system, and have received the acknowledgement from the FDA that the 510(k) application was received.

Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

See News Rankings